A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)

NCT00463242 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

501

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Agomelatine
DRUG: paroxetine
DRUG: placebo

Sponsor

Novartis